Peptides DB
Research-centric peptide and protocol reference hub

NAD+ (Nicotinamide Adenine Dinucleotide) vs PE 22-28

Updated July 28, 2026 · Reviewed by the PeptidesDB Editorial team

NAD+ (Nicotinamide Adenine Dinucleotide): Research use — not FDA-approvedPE 22-28: Research use — not FDA-approved

A data-driven comparison of NAD+ (Nicotinamide Adenine Dinucleotide) and PE 22-28 (also searched as PE 22-28 vs NAD+ (Nicotinamide Adenine Dinucleotide)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

NAD+ (Nicotinamide Adenine Dinucleotide) centers on metabolic, while PE 22-28 leans toward metabolic. On indexed research, NAD+ (Nicotinamide Adenine Dinucleotide) is ahead (NAD+ (Nicotinamide Adenine Dinucleotide): 22 studies, Human evidence; PE 22-28: 17, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • NAD+ (Nicotinamide Adenine Dinucleotide) is strongest for metabolic; PE 22-28 for metabolic.
  • Evidence: NAD+ (Nicotinamide Adenine Dinucleotide) Human evidence (22 studies) vs PE 22-28 Human evidence (17).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

NAD+ (Nicotinamide Adenine Dinucleotide): Healing 4.0, Muscle 2.0, Metabolic 5.0, Neuro 3.0, Sleep 2.0, Immune 4.0, Skin 1.0 — PE 22-28: Healing 1.0, Muscle 0.0, Metabolic 3.0, Neuro 0.0, Sleep 0.0, Immune 2.0, Skin 0.0Healing & recovery — 4.0 / 5 · NAD+ (Nicotinamide Adenine Dinucleotide)Muscle & body comp — 2.0 / 5 · NAD+ (Nicotinamide Adenine Dinucleotide)Metabolic & appetite — 5.0 / 5 · NAD+ (Nicotinamide Adenine Dinucleotide)Neuro & mood — 3.0 / 5 · NAD+ (Nicotinamide Adenine Dinucleotide)Sleep & circadian — 2.0 / 5 · NAD+ (Nicotinamide Adenine Dinucleotide)Inflammation & immune — 4.0 / 5 · NAD+ (Nicotinamide Adenine Dinucleotide)Skin & aesthetics — 1.0 / 5 · NAD+ (Nicotinamide Adenine Dinucleotide)Healing & recovery — 1.0 / 5 · PE 22-28Metabolic & appetite — 3.0 / 5 · PE 22-28Inflammation & immune — 2.0 / 5 · PE 22-28HealingMuscleMetabolicNeuroSleepImmuneSkin
NAD+ (Nicotinamide Adenine Dinucleotide)PE 22-28

At a glance

Essential Cellular Coenzyme & Anti-Aging Therapy

Strongest: MetabolicStudies: 22Level: Extensively Studied
PE 22-28Human evidence

TREK-1 Channel Blocker | Shortened Spadin Analog

Strongest: MetabolicStudies: 17Level: Emerging

NAD+ (Nicotinamide Adenine Dinucleotide) vs PE 22-28: side-by-side

MetricNAD+ (Nicotinamide Adenine Dinucleotide)PE 22-28
ClassLongevityCognitive
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidenceHuman evidence
Studies indexed2217
Research levelExtensively StudiedEmerging
Strongest effectMetabolic & appetiteMetabolic & appetite
Healing & recovery4.01.0
Muscle & body comp2.00.0
Metabolic & appetite5.03.0
Neuro & mood3.00.0
Sleep & circadian2.00.0
Inflammation & immune4.02.0
Skin & aesthetics1.00.0

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyNAD+ (Nicotinamide Adenine Dinucleotide)PE 22-28
MechanismCoenzyme in redox reactions
RouteIntravenous infusion

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is NAD+ (Nicotinamide Adenine Dinucleotide)?

### Summary NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.

Full NAD+ (Nicotinamide Adenine Dinucleotide) profile, mechanism & studies →

What is PE 22-28?

### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.

Full PE 22-28 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingNAD+ (Nicotinamide Adenine Dinucleotide)4.0/5 effect signal
MuscleNAD+ (Nicotinamide Adenine Dinucleotide)2.0/5 effect signal
MetabolicNAD+ (Nicotinamide Adenine Dinucleotide)5.0/5 effect signal
NeuroNAD+ (Nicotinamide Adenine Dinucleotide)3.0/5 effect signal
SleepNAD+ (Nicotinamide Adenine Dinucleotide)2.0/5 effect signal
InflammationNAD+ (Nicotinamide Adenine Dinucleotide)4.0/5 effect signal
SkinNAD+ (Nicotinamide Adenine Dinucleotide)1.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack NAD+ (Nicotinamide Adenine Dinucleotide) and PE 22-28?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

NAD+ (Nicotinamide Adenine Dinucleotide) vs PE 22-28: side effects

NAD+ (Nicotinamide Adenine Dinucleotide)

No community-reported effects logged yet.

PE 22-28

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

NAD+ (Nicotinamide Adenine Dinucleotide) has 22 approved studies indexed (Human evidence), and PE 22-28 has 17 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is NAD+ (Nicotinamide Adenine Dinucleotide) or PE 22-28 better?

It depends on your goal. NAD+ (Nicotinamide Adenine Dinucleotide) is strongest for metabolic; PE 22-28 for metabolic. NAD+ (Nicotinamide Adenine Dinucleotide) has more indexed studies (22). See the goal-by-goal breakdown above.

Is NAD+ (Nicotinamide Adenine Dinucleotide) or PE 22-28 better for weight loss?

NAD+ (Nicotinamide Adenine Dinucleotide) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.

Is NAD+ (Nicotinamide Adenine Dinucleotide) or PE 22-28 better for muscle?

NAD+ (Nicotinamide Adenine Dinucleotide) leads on the muscle & body-composition axis (2.0/5).

Which has more research, NAD+ (Nicotinamide Adenine Dinucleotide) or PE 22-28?

NAD+ (Nicotinamide Adenine Dinucleotide) has 22 approved studies indexed (Human evidence); PE 22-28 has 17 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack NAD+ (Nicotinamide Adenine Dinucleotide) and PE 22-28?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of NAD+ (Nicotinamide Adenine Dinucleotide) vs PE 22-28?

NAD+ (Nicotinamide Adenine Dinucleotide): no community-reported effects logged yet. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is NAD+ (Nicotinamide Adenine Dinucleotide) or PE 22-28 FDA-approved?

NAD+ (Nicotinamide Adenine Dinucleotide) is a research-use compound and is not FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is PE 22-28 better than NAD+ (Nicotinamide Adenine Dinucleotide)?

For metabolic, PE 22-28 has the edge; for metabolic, NAD+ (Nicotinamide Adenine Dinucleotide) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

NAD+ (Nicotinamide Adenine Dinucleotide) and PE 22-28 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 28, 2026.